A bill to ban anticompetitive terms in facility and insurance contracts that limit access to higher quality, lower cost care.
Summary
S.4027 bans anti-steering, all-or-nothing, and most-favored-nation contract clauses that hospital systems use to block insurers from directing patients to lower-cost providers. The market has already priced in momentum: $CI +3.7%, $HUM +12.5%, $CVS +6.4% in the past 7 days. Bill is in early stages (referred to HELP Committee) with no spending authorized — the mechanism is pure regulatory leverage shift from hospitals to insurers.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.S.4027 shifts negotiating leverage from hospital systems to health insurers by banning four specific anticompetitive contract clauses.
- 2.$HUM is the most leveraged beneficiary with 7-day gains of +12.5%, reflecting its heavy Medicare Advantage concentration where anti-steering clauses are most restrictive.
- 3.Zero taxpayer spending — mechanism is pure regulatory prohibition; savings flow through lower insurance premiums and improved insurer margins.
- 4.Bill is in early HELP Committee stage; hospital industry opposition is strong, making passage uncertain before late 2026 at earliest.
Market Implications
The market has already begun pricing in this legislative momentum. $HUM at $242.03 is up 12.5% in 7 days and 39.6% in 30 days — the largest moves among the three insurers, consistent with its highest exposure to Medicare Advantage networks where hospital anti-steering clauses are most prevalent. $CVS at $82.97 (near its 52-week high of $85.15) shows the market is baking in both the regulatory benefit and CVS's vertical integration advantage. $CI at $285.9 is the most modest beneficiary given its larger self-insured employer book (where network flexibility is less constrained). Watch for HELP Committee hearing announcements as the next catalyst — any scheduled hearing would validate that the bill has moved from introduction to active consideration, likely triggering another leg up for insurers and a corresponding sell-off for hospital REITs and operators like $HCA and $CYH.
Full Analysis
- What happened: On March 9, 2026, Senator Husted (R-OH) introduced S.4027, the Healthy Competition for Better Care Act. The bill was read twice and referred to the Senate HELP Committee. It is in early procedural stages. The bill prohibits four specific types of anticompetitive contract terms: (A) restrictions on steering or incentivizing patients to specific providers, (B) requirements to contract with all affiliates of a hospital system (all-or-nothing clauses), (C) requirements to accept payment rates for affiliates not party to the agreement, and (D) most-favored-nation clauses that block other insurers from paying lower rates. 2) Money trail: Zero taxpayer dollars. The bill operates entirely through regulatory prohibition — the government does not spend, it forbids. Cost savings flow to the private sector: lower premium growth as insurers gain leverage to exclude high-cost hospitals from networks. CBO would likely score this as reducing federal healthcare spending (Medicare, FEHB) through lower insurance costs, but no direct appropriation is authorized. 3) Structural winners and losers: Winners are insurers ($CI, $HUM, $CVS) who gain negotiating leverage over hospital systems. Losers are hospital systems that rely on market power to maintain above-market rates — large nonprofit systems like HCA, Community Health Systems ($CYH), and academic medical centers will face margin pressure if they lose their ability to force all-or-nothing contracts. Insurers with vertically integrated provider networks (CVS/Oak Street, UHG/Optum) benefit double — they can steer to their own facilities while competitors struggle to build networks. 4) Market data analysis: Real 7-day price action shows $HUM leading with +12.5%, $CVS at +6.4%, $CI at +3.7%. $HUM's extreme movement reflects its disproportionate exposure to Medicare Advantage, where hospital anti-steering clauses are most aggressive and where Humana's market share is highest. The 30-day changes tell a deeper story: $HUM +39.6%, $CVS +15.5%, $CI +7.2%. This suggests the bill is not the sole catalyst — $HUM's massive run may also reflect unrelated Medicare Advantage rate finalization or rate advantage news. However, the 7-day acceleration across all three confirms the bill is a marginal positive driver. 5) Timeline: Referred to HELP Committee — no hearing or markup scheduled. The 119th Congress runs through January 2027. Path to passage requires committee approval, floor vote in the Senate, identical bill in the House, and presidential signature. Given the partisan divide on healthcare, this bill faces significant headwinds from hospital industry lobbying. The earliest realistic enactment is late 2026, but more likely it serves as a signaling vehicle for the 2028 Republican platform.
Intelligence Surface
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
No confirming evidence found yet from contracts, insider trades, or congressional activity
What the bill does
Regulatory prohibition — bans contract clauses that restrict insurers from steering patients, require all-or-nothing deals with hospital affiliates, or mandate most-favored-nation pricing.
Who must act
Health insurers offering group or individual health coverage (Cigna, Humana, CVS Health, and other plans).
What happens
Increased ability to narrow networks, steer patients to lower-cost providers, and negotiate tiered pricing without being forced into broad system-wide contracts.
Stock impact
Cigna's network design flexibility improves — it can more aggressively steer members to its preferred lower-cost providers, reducing medical cost ratio (MCR) pressure. Strong self-insured employer book (over 80% of medical members) gains immediate network restructuring optionality.
What the bill does
Regulatory prohibition — bans contract clauses that restrict insurers from steering patients, require all-or-nothing deals with hospital affiliates, or mandate most-favored-nation pricing.
Who must act
Health insurers offering group or individual health coverage.
What happens
Greater leverage over hospital systems in network negotiations, particularly for Medicare Advantage plans where Humana has highest market concentration.
Stock impact
Humana's MA-heavy business (over 80% of revenue from Medicare) benefits disproportionately — hospital anti-steering clauses are most restrictive in MA networks. Ability to exclude high-cost hospitals from narrow MA networks directly improves Medicare margin performance.
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
Association Health Plans Act
Veteran Caregiver Reeducation, Reemployment, and Retirement Act
Veterans’ ACCESS Act of 2025
Protecting Health Care and Lowering Costs Act
Living Donor Protection Act of 2025
To amend the Employee Retirement Income Security Act of 1974 to ensure that pharmacy benefit managers are considered fiduciaries, and for other purposes.
Protecting Health Care and Lowering Costs Act of 2025
Medicare for All Act
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Implementing Schedule Policy/Career in the Excepted Service
This executive order expands the Schedule Policy/Career excepted service category, transferring certain federal positions from competitive service to at-will employment to facilitate removal for poor performance or misconduct. It directs agency heads to petition for reclassification of policy-influencing roles, mandates performance bonus pools for these employees, and amends civil service rules to exempt them from standard adverse action procedures.
Realigning United States Core Childhood Vaccine Recommendations with Best Practices from Peer, Developed Countries
This executive order directs the CDC and ACIP to review and potentially update the U.S. childhood vaccine schedule to align with recommendations from peer developed countries, which recommend fewer vaccines. It maintains insurance coverage for all currently available vaccines without cost sharing and emphasizes protecting religious liberty and parental authority.
Promoting Efficiency, Accountability, and Performance in Federal Contracting
This executive order mandates that federal agencies default to using fixed-price contracts for procurement, shifting away from cost-reimbursement models. It requires written justification and senior-level approval for any non-fixed-price contract over certain dollar thresholds (e.g., $10M for most agencies, $100M for the Department of War), and directs agencies to review and renegotiate their 10 largest non-fixed-price contracts within 90 days. The order also tasks OMB with implementation guidance and the Federal Acquisition Regulatory Council with proposing regulatory amendments within 120 days.